Cardiac muscle lesions associated with chronic administration of methamphetamine in rats.

Cardiovascular complications associated with methamphetamine abuse have increasingly been reported. However, chronic cardiotoxicity of methamphetamine is not experimentally well documented. In this study, methamphetamine (1 mg/kg/day) was subcutaneously injected into 5-week-old male Wistar Kyoto rats (n = 30). Age- and sex-matched Wistar Kyoto rats served as controls (n = 30). After 14 and 56 days, hearts were examined by light and electron microscopy. Foci of myocytic degeneration and necrosis appeared in the sub-endocardial areas on day 14 of methamphetamine exposure. Myocytic degeneration and necrosis became more extensive on day 56. At this stage, myocytolysis, contraction bands, atrophied myocytes, and spotty fibrosis were patchily distributed throughout the myocardium in most of rats treated with methamphetamine. The accompanying ultrastructural features included marked degeneration of cardiac mitochondria with fractured and disrupted cristae, hypercontraction of myofibrils, and loss of myofilament. In contrast, cardiac myocyte lesions were not observed in control rats. These myocardial lesions in rats treated with methamphetamine for 56 days resemble the cardiomyopathy associated with methamphetamine abuse in humans.

[1]  H. Nakajima,et al.  Sudden death due presumably to internal use of methamphetamine. , 1993, Forensic science international.

[2]  S. Goldberg,et al.  Pharmacological mechanisms in the cardiovascular effects of methamphetamine in conscious squirrel monkeys , 1992, Pharmacology Biochemistry and Behavior.

[3]  R. E. Hicks,et al.  Clinical effects of daily methamphetamine administration. , 1991, Clinical neuropharmacology.

[4]  R. Hong,et al.  Cardiomyopathy associated with the smoking of crystal methamphetamine. , 1991, JAMA.

[5]  R. Derlet,et al.  Methamphetamine. Stimulant of the 1990s? , 1990, The Western journal of medicine.

[6]  P. Shah,et al.  Myocardial infarction after inhalation of methamphetamine. , 1990, The New England journal of medicine.

[7]  A. Cho Ice: A New Dosage Form of an Old Drug , 1990, Science.

[8]  G. Packe,et al.  Acute myocardial infarction caused by intravenous amphetamine abuse. , 1990, British heart journal.

[9]  J. Veenstra,et al.  [Myocardial infarct following use of amphetamine derivatives]. , 1990, Nederlandsch tijdschrift voor geneeskunde.

[10]  L. Jacobs Reversible dilated cardiomyopathy induced by methamphetamine , 1989, Clinical cardiology.

[11]  A. Kashiwagi,et al.  [A case of hypertrophic cardiomyopathy associated with amphetamine abuse]. , 1989, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine.

[12]  R. F. Shaw,et al.  Cocaine- and methamphetamine-related deaths in San Diego County (1987): homicides and accidental overdoses. , 1989, Journal of forensic sciences.

[13]  R. Derlet,et al.  Amphetamine toxicity: experience with 127 cases. , 1989, The Journal of emergency medicine.

[14]  K. Puder,et al.  Illicit methamphetamine: analysis, synthesis, and availability. , 1988, The American journal of drug and alcohol abuse.

[15]  D. Goldstein,et al.  Reversibility of catecholamine-induced dilated cardiomyopathy in a child with a pheochromocytoma. , 1987, The New England journal of medicine.

[16]  H. Tazelaar,et al.  Cocaine and the heart. , 1987, Human pathology.

[17]  B. Kiss,et al.  In vivo interaction between amphetamine and beta-adrenoceptor blockers: effects on the release of norepinephrine from mouse heart. , 1982, Pharmacological research communications.

[18]  J. Rajs,et al.  Cardiac lesions in intravenous drug addicts. , 1979, Forensic science international.

[19]  A. Roche,et al.  Cardiomyopathy associated with amphetamine administration. , 1976, American heart journal.

[20]  D. Reichenbach,et al.  Catecholamines and cardiomyopathy: The pathogenesis and potential importance of myofibrillar degeneration , 1970 .

[21]  E. Zalis,et al.  The pathophysiology of acute amphetamine poisoning with pathologic correlation. , 1967, The Journal of pharmacology and experimental therapeutics.